The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models
Open accessAbstract
Obesity and diabetes are leading causes of cardiovascular morbidity and mortality. Although extensive strides have been made in the treatments for non-diabetic atherosclerosis and its complications, for patients with diabetes, these therapies provide less benefit for protection from cardiovascular disease (CVD). These considerations spur the concept that diabetes-specific, disease-modifying therapies are essential to identify, especially as the epidemics of obesity and diabetes continue to expand. Hence, as hyperglycemia is a defining feature of diabetes, it is logical to probe the impact of the specific consequences of hyperglycemia on the vessel wall, immune cell perturbation and endothelial dysfunction – all harbingers to the development of CVD. In this context, high levels of blood glucose stimulate the formation of the irreversible advanced glycation end products, the products of nonenzymatic glycation and oxidation of proteins and lipids. AGEs accumulate in diabetic circulation and tissues and the interaction of AGEs with their chief cellular receptor, receptor for AGE or RAGE, contributes to vascular and immune cell perturbation. The cytoplasmic domain of RAGE lacks endogenous kinase activity; the discovery that this intracellular domain of RAGE binds to the formin, DIAPH1, and that DIAPH1 is essential for RAGE ligand-mediated signal transduction, identifies the specific cellular means by which RAGE functions and highlights a new target for therapeutic interruption of RAGE signaling. In human subjects, prominent signals for RAGE activity include the presence and levels of two forms of soluble RAGE, sRAGE and endogenous secretory (es) RAGE. Further, genetic studies have revealed single nucleotide polymorphisms (SNPs) of the AGER gene (AGER is the gene encoding RAGE) and DIAPH1, which display associations with CVD. This Review presents current knowledge regarding the roles for RAGE and DIAPH1 in the causes and consequences of diabetes, from obesity to CVD. Studies both from human subjects and animal models are presented to highlight the breadth of evidence linking RAGE and DIAPH1 to the cardiovascular consequences of these metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Self-citationTian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Self-citationVascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
Rage and arthritis: The G82S polymorphism amplifies the inflammatory response
Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y., Lalla, E., Chitnis, S., Monteiro, J., Stickland, M. H., et al. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363861 · Cited by 383
Self-citationEpicardial adipose tissue and cardiovascular diseases
Ansaldo, A. M., Montecucco, F., Sahebkar, A., Dallegri, F., & Carbone, F. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.089 · Cited by 247
Tanikawa, T., Okada, Y., Tanikawa, R., & Tanaka, Y. (2009) · Journal of Vascular Research · doi:10.1159/000226225 · Cited by 191 · cited 3×
“Consistent with roles for RAGE ligands in these processes, exposure of vascular SMCs to AGEs increased calcification, at least in part through activation of p38 mitogenactivated protein kinase (MAPK) (58, 59).”
BackgroundAleshin, A., Ananthakrishnan, R., Li, Q., Rosario, R., Lu, Y., Qu, W., Song, F., Bakr, S., Szabolcs, M., D'Agati, V., et al. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01210.2007 · Cited by 143
Self-citationPeripheral Arterial Disease, Diabetes, and Mortality
Leibson, C. L., Ransom, J. E., Olson, W., Zimmerman, B. R., O’Fallon, W. M., & Palumbo, P. J. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2843 · Cited by 137
Cited by
COVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482
Alber, J., Alladi, S., Bae, H., Barton, D. A., Beckett, L. A., Bell, J. M., Berman, S. E., Biessels, G. J., Black, S. E., Bos, I., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.001 · Cited by 443
Rungratanawanich, W., Qu, Y., Wang, X., Essa, M. M., & Song, B.-J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00561-7 · Cited by 411
Li, Y., Peng, Y., Shen, Y., Zhang, Y., Liu, L., & Yang, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2076064 · Cited by 156
Singh, H., & Agrawal, D. K. (2022) · Drug Development Research · doi:10.1002/ddr.21971 · Cited by 57
Metadata
- Authors
- Egaña-Gorroño, L., López-Díez, R., Yepuri, G., Ramirez, L. S., Reverdatto, S., Gugger, P. F., Shekhtman, A., Ramasamy, R., & Schmidt, A. M.
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2020-03-10
- Volume
- 7
- Pages
- 37-37
- ISSN
- 2297-055X (ISSN-L)
- OpenAlex
- W3009862485
- Cited by
- 211
- References
- 14
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models. https://app.cochat.ai/papers/10.3389/fcvm.2020.00037
- The paper
- Egaña-Gorroño, L., López-Díez, R., Yepuri, G., Ramirez, L. S., Reverdatto, S., Gugger, P. F., Shekhtman, A., Ramasamy, R., & Schmidt, A. M. (2020). Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2020.00037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.